脂蛋白脂酶降解与代谢异常性疾病  

Lipoprotein lipase degradation and metabolic disorders

作　　者：成海鹏 尹卫东[1] 唐朝克[1] 

机构地区：[1]南华大学心血管病研究所,动脉硬化学湖南省重点实验室,湖南省分子靶标新药研究协同创新中心医学研究中心,湖南省衡阳市421001

出　　处：《中国动脉硬化杂志》2017年第5期513-518,共6页Chinese Journal of Arteriosclerosis

基　　金：国家自然科学基金项目(81270269;81370377;81570408);南华大学分子靶标新药研究协同创新中心研究生创新性实验项目(0223-0002-D0033)

摘　　要：脂蛋白脂酶(LPL)的蛋白降解是调节机体LPL水平的重要途径之一,新近研究发现LPL降解受到多种相关蛋白的调控,LPL的降解过程主要包括细胞内降解和细胞外降解两部分。LPL的细胞内降解主要是相关蛋白调控新生的LPL转移到溶酶体中降解;LPL的细胞外降解包括细胞外成熟的LPL和循环中的LPL降解两个过程,主要是LPL被重新摄取或转运至细胞内,随内体聚集到溶酶体降解。因此,本文针对不同时期的LPL降解及其调控进行归纳整理,并阐述LPL降解与代谢异常性疾病之间的关系。Lipoprotein lipase （LPL） degradation is one of the important ways to regulate the level of LPL. Recently, it has been found that LPL degradation is regulated by a variety of related proteins, the process of LPL degradation mainly includes two parts：intracellular degradation and extracellular degradation. The intracellular degradation of LPL means a large amount of newborn LPL which were transferred to the lysosome for degradation via the related proteins. The extracellular degradation of LPL means mature LPL which were re-uptaked or transported into the cell under the action of the related proteins, and then gathered into lysosomal for degradation. This article will review the LPL in the process of LPL protein synthesis, transportation and biological functions, and then elucidate the relationship between its degradation and metabolic syndrome.

关 键 词：脂蛋白脂酶 溶酶体降解 动脉粥样硬化 糖尿病心肌病 肥胖 

分 类 号：R363[医药卫生—病理学]